Follow this preprint
Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
View ORCID ProfileSimeon I. Taylor, Hua-Ren Cherng, Zhinous Shahidzadeh Yazdi, May E. Montasser, Hilary B. Whitlatch, View ORCID ProfileBraxton D. Mitchell, Alan R. Shuldiner, Elizabeth A. Streeten, Amber L. Beitelshees
doi: https://doi.org/10.1101/2023.03.07.23286875
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Simeon I. Taylor
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Hua-Ren Cherng
2Department of Radiation Oncology University of Maryland School of Medicine Baltimore, MD 20201 USA
Zhinous Shahidzadeh Yazdi
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
May E. Montasser
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Hilary B. Whitlatch
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Braxton D. Mitchell
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Alan R. Shuldiner
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Elizabeth A. Streeten
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA
Amber L. Beitelshees
1Department of Medicine Division of Endocrinology, Diabetes, and Nutrition University of Maryland School of Medicine Baltimore, MD 20201 USA

Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Posted June 12, 2023.
Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
Simeon I. Taylor, Hua-Ren Cherng, Zhinous Shahidzadeh Yazdi, May E. Montasser, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Elizabeth A. Streeten, Amber L. Beitelshees
medRxiv 2023.03.07.23286875; doi: https://doi.org/10.1101/2023.03.07.23286875
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (420)
- Allergy and Immunology (744)
- Anesthesia (217)
- Cardiovascular Medicine (3208)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13211)
- Forensic Medicine (19)
- Gastroenterology (887)
- Genetic and Genomic Medicine (5039)
- Geriatric Medicine (469)
- Health Economics (770)
- Health Informatics (3167)
- Health Policy (1121)
- Hematology (419)
- HIV/AIDS (997)
- Medical Education (467)
- Medical Ethics (125)
- Nephrology (512)
- Neurology (4783)
- Nursing (253)
- Nutrition (708)
- Oncology (2462)
- Ophthalmology (698)
- Orthopedics (277)
- Otolaryngology (336)
- Pain Medicine (318)
- Palliative Medicine (89)
- Pathology (528)
- Pediatrics (1272)
- Primary Care Research (546)
- Public and Global Health (7343)
- Radiology and Imaging (1661)
- Respiratory Medicine (962)
- Rheumatology (471)
- Sports Medicine (413)
- Surgery (532)
- Toxicology (69)
- Transplantation (227)
- Urology (199)